08:03 AM EDT, 05/14/2024 (MT Newswires) -- Lexicon Pharmaceuticals ( LXRX ) said Tuesday that a post hoc analysis of clinical data from a phase 3 study showed that its diabetes and kidney disease treatment Inpefa reduced the risk of heart failure events in certain patients.

According to the company, Inpefa reduced the risk of heart failure-related events in various patient populations, including those with preserved ejection fraction, a type of heart failure typically associated with obesity and type 2 diabetes.

Data from a total of 1,932 patients were included in the analysis, of which 18.1% of the patients experienced a primary endpoint event. The new analysis also found that patients at risk of obesity benefited from the glucose-regulating effects of Infepa therapy, the company said.

Shares of the biopharmaceutical firm rose more than 6% in recent premarket activity on Tuesday.

Price: 2.00, Change: +0.13, Percent Change: +6.95